United Therapeutics (UTHR) Tops Q3 EPS by 73c, Revenues Beat

United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $3.98, $0.73 better than the analyst estimate of $3.25. Revenue for the quarter came in at $412.7 million versus the consensus estimate of $380.43 million.

"We are pleased to see continued growth in the number of U.S. patients treated with our prostacyclin product franchise during the quarter," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "We\'ve been busy bringing in exceptional new pipeline opportunities and advancing our six Phase III clinical trials."

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Can global equities keep rising? UBS sees these factors driving upside
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold